Top 5 Most Read Q&As of 2023

Below is a list of the most read written Q&As featured on Applied Clinical Trials in 2023.

Mural Health Technologies, Inc., a new global provider of clinical trials technology, announced the launch of its new participant-facing technology platform, Mural Link at the CNS Summit in November. Sam Whitaker, co-founder and co-CEO of Mural Health, is no stranger to patient-facing technology. He founded Greenphire over 15 years ago to address participant payment technology. In this Q&A with Applied Clinical Trials, Whitaker discusses his time in the industry and patient needs in the current clinical trials market.

Read the Q&A here.

Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis. Shukla explains the challenges in conducting a large trial for a rare disease and the company's approach to overcoming them. The trial design, incorporating patient feedback and decentralized clinical trials, are seen as essential for clinical trial and commercialization success.

Read the Q&A here.

Clinical trials, says neuroscientist Antonella Santuccione Chadha,MD, usually have one thing in common: Their results are not stratified on the basis of sex. That lack of sex- and gender-based analysis, says Santuccione Chadha, chief medical officer, Altoida, and pro bono CEO of the Women’s Brain Project, negatively impacts the whole of society. Santuccione Chadha spoke with Applied Clinical Trials.

Read the Q&A here.

Applied Clinical Trials chatted with Ashley Moultrie, director of diversity, equity, and inclusion (DEI) and community engagement for Javara, an integrated research company that provides clinical research access to patients at the point the care. Javara achieves this by embedding staff and infrastructure into large healthcare organizations.

Read the Q&A here.

David Dodd, CEO of GeoVax, discusses the company's unique vaccine development strategy, clinical trials, and approach to serving patient populations often overlooked by conventional vaccines. The conversation sheds light on the company's specialized focus on immunocompromised patients, their clinical trial operations, and their expectations for the future.

Read the Q&A here.